Is Nimacimab Approved? CB1 Antibody Status and Timeline (2026)
No. Nimacimab is still a Phase 2a asset. It is one of the more unusual non-incretin obesity stories, but it is not close to approval.
Current stage
Phase 2a
Approval read
Not approved.
Likely window
2029 or later if the program continues to de-risk.
Next step
Show that the antibody approach can revive CB1 biology in a way that feels cleaner and more durable.
Direct answer
No. Nimacimab is still a Phase 2a asset. It is one of the more unusual non-incretin obesity stories, but it is not close to approval.
Status facts for search and AI answers
What this Nimacimab status page answers
Compound
Nimacimab
Nimacimab is tracked as a CB1 antibody program from Skye Bioscience.
Approval read
Not approved.
No. Nimacimab is still a Phase 2a asset. It is one of the more unusual non-incretin obesity stories, but it is not close to approval.
Likely window
2029 or later if the program continues to de-risk.
The likely window is a FormBlends tracking read, not a guarantee of patient access.
Next step
Show that the antibody approach can revive CB1 biology in a way that feels cleaner and more durable.
This is the milestone most likely to change the page's answer.
Decision path
What does Nimacimab's status mean for access?
Nimacimab's approval status should be read as a regulatory signal, not a shortcut to buying or prescribing. The useful decision is whether this is approved, decision-stage, investigational, or simply worth monitoring.
- Compound
- Nimacimab
- Stage
- Phase 2a
- Approval read
- Not approved.
- Window
- 2029 or later if the program continues to de-risk.
Step 1
Classify availability
Phase 2a CB1-antibody program with novelty value and a long timeline still ahead.
Read compound pageStep 2
Watch required milestone
Show that the antibody approach can revive CB1 biology in a way that feels cleaner and more durable.
Open pipeline trackerStep 3
Use current-care rules
If you need care now, separate trial-stage news from provider-reviewed GLP-1 options that can actually be prescribed.
Compare care routesWhat the status means now
Phase 2a CB1-antibody program with novelty value and a long timeline still ahead.
Nimacimab matters because it tests whether the field can revisit appetite-signaling biology with a more modern format.
What needs to happen next
Show that the antibody approach can revive CB1 biology in a way that feels cleaner and more durable.
What FormBlends is watching
- Whether the CB1-antibody framing produces a clearer safety story
- How seriously the market starts taking it
- Whether Skye can keep the program strategically visible
What could delay the timeline
- Early-stage attrition
- Residual skepticism around CB1 biology
- Sponsor-scale limitations